| Ytd | 190.04% | |
| 1y | 190.04% |
| Open | 107.01 | Prev Close | 106.04 | Low | 107.01 | High | 112.89 | Mkt Cap | 4.57B |
| Vol | 513.29K | Avg Vol | 706.40K | EPS | -3.14 | P/E | -34.86 | Forward P/E | -39.37 |
| Beta | N/A | Short Ratio | 5.22 | Inst. Own | 80.12% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 106.69 | 200-d Avg | 81.84 | 1yr Est | 161.00 |
MANE News
MANE's main drug candidate is VDPHL01. This asset already has encouraging male and female data for h
Veradermics, Incorporated (NYSE:MANE), a dermatologist-founded, late-stage biopharmaceutical company
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded,
Veradermics, Incorporated (NYSE: MANE - Get Free Report)'s stock price gapped up before the market o
Citigroup analyst Geoff Meacham maintains Veradermics (NYSE:MANE) with a Buy and raises the price
Veradermics Incorporated (NYSE:MANE) on Wednesday released topline results from an open-label Phase
Veradermics reported positive phase 2 data for VDPHL01, showing hair growth and favorable safety in
Needham analyst Serge Belanger maintains Veradermics (NYSE:MANE) with a Buy and raises the price
Veradermics, Incorporated (MANE) Discusses Positive Female Results From Phase II Study of VDPHL01 fo
Gainers China Pharma Holding (AMEX:CPHI) shares moved upwards by 67.6% to $1.03 during Wednesday
Veradermics NYSE: MANE said results from the female arms of Study 207, a phase II open-label trial o
US stocks close higher, Dow Jones up 100 points, PayPal shares rise on $53 billion acquisition propo
VDPHL01, a novel orally-administered extended-release minoxidil formulation, achieved fast onset of
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded,
B. Riley Securities analyst Mayank Mamtani initiates coverage on Veradermics (NYSE:MANE) with a B
Jefferies analyst Roger Song maintains Veradermics (NYSE:MANE) with a Buy and raises the price ta
LifeSci Capital analyst Rami Katkhuda initiates coverage on Veradermics (NYSE:MANE) with a Outper
Wall Street analysts changed outlook on top names: ODTX, MOBI, MANE. See analyst ratings page for al
Needham analyst Serge Belanger initiates coverage on Veradermics (NYSE:MANE) with a Buy rating an
Veradermics, Incorporated (NYSE:MANE), a dermatologist-founded, late clinical-stage biopharmaceutica
Veradermics, Incorporated (NYSE:MANE), a dermatologist-founded, late clinical-stage biopharmaceutica
U.S. stocks were lower, Dow Jones fell 0.1% on Monday. XOMA shares rose on Ligand's plans to acq